MindImmune
Develops immune-focused therapies for neurodegenerative diseases, including Alzheimer’s disease
$5MStrategic
Role not disclosedAD
Alzheimer’s Drug Discovery Foundation
Activity from announced rounds
Activity in this selectionUnited States · Mar 31, 2026 · Mar 1, 2026
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $5M 1 disclosed · full round size, not this investor’s share